Fig 1.
General formula for calculating productivity loss.
TPC = Total productivity costs (in US$ 2005), NTD = Neglected Tropical Disease, c = Country, y = Year, PS1 = Number of prevalent cases aged 15+ years with sequela 1, PS2 = Number of prevalent cases aged 15+ years with sequela 2, PLs1 = % productivity loss related to sequela 1 of NTD, PLs2 = % productivity loss related to sequela 2 of NTD, I = GDP per capita in the lowest quintile, D = Annual discount rate, t = Time (years beyond 2010).
Table 1.
Annual percentages of productivity loss used in the calculations of economic benefit.
Fig 2.
General formula for calculating out-of-pocket payments.
TDC = Total out-of-pocket payments (in US$ 2005), NTD = Neglected tropical disease, c = Country, y = Year, PS1 = Number of persons with sequela 1 of NTD, PS2 = Number of persons with sequela 2 of NTD, DCS1 = Annual out-of-pocket payments relating to sequela 1 (per WHO region or country), DCS2 = Annual out-of-pocket payments relating to sequela 2 (per WHO region or country), PT = Percentage of patients treated, PP = Percentage of patients paying for the treatment, D = Annual discount rate, t = Time (years).
Table 2.
Out-of-pocket payments, percentage of patients being treated and percentage of patients paying for treatment according to the literature, used in the calculations for Chagas disease (I$—International dollars).
Table 3.
Values used to calculate out-of-pocket payments (OPPs) for visceral leishmaniasis (I$—International dollars).
Table 4.
Values used to calculate out-of-pocket payments (OPPs) for human African trypanosomiasis (I$—International dollars).
Table 5.
Upper and lower limits used in the sensitivity analyses.
Fig 3.
Productivity loss due to Chagas chronic heart disease according to the counterfactual and target achievement scenarios (millions I$—International dollars).
Total global loss per year in the counterfactual scenario (blue) and target achievement scenario (orange). The economic benefit is the difference between both scenarios.
Table 6.
Total economic benefit from productivity loss averted, base case estimates and 2.5th and 97.5th percentiles (billions I$—International dollars and US$—US dollars 3% discounting from 2010).
Fig 4.
Global economic benefit (productivity loss averted) for IDM NTDs, for the period 2011–2030 (billions I$—International dollars).
Global economic benefit from reaching the targets for IDM NTDs, lower and upper estimates from sensitivity analysis. Global economic benefit per disease.
Fig 5.
Regional economic benefit (productivity loss averted) for IDM NTDs, for the period 2011–2030 (billions I$—International dollars) per WHO region.
Regional economic benefit from reaching the targets for IDM NTDs, for the period 2011–2030 per WHO region.
Table 7.
Total economic benefit from out-of-pocket payments averted, base case estimates and 2.5th and 97.5th percentiles (billions I$—International dollars and US$—US dollars) discounting 3% from 2010.
Fig 6.
Global economic benefit (out-of-pocket payments averted) for IDM NTDs, for the period 2011–2030 (billions I$—International dollars).
Total economic benefit from out-of-pocket payments averted, base case estimates and 2.5th and 97.5th percentiles (billions I$—international dollars), discounting 3% from 2010.